A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee

Simple item page
dc.contributor.authorCohen, S.
dc.contributor.authorProudman, S.
dc.contributor.authorKivitz, A.
dc.contributor.authorBurch, F.
dc.contributor.authorDonohue, J.
dc.contributor.authorBurstein, D.
dc.contributor.authorSun, Y.
dc.contributor.authorBanfield, C.
dc.contributor.authorVincent, M.
dc.contributor.authorNi, L.
dc.contributor.authorZack, D.
dc.date.issued2011
dc.description.abstractINTRODUCTION: AMG 108 is a fully human, immunoglobulin subclass G2 (IgG2) monoclonal antibody that binds the human interleukin-1 (IL-1) receptor type 1, inhibiting the activity of IL-1a and IL-1b. In preclinical studies, IL-1 inhibition was shown to be beneficial in models of osteoarthritis (OA). The purpose of this two-part study was to evaluate the safety and pharmacokinetics (PK; Part A) and clinical effect (Part B) of AMG 108 in a double-blind, placebo-controlled, multiple-dose study in patients with OA of the knee. METHODS: In Part A, patients received placebo or AMG 108 subcutaneously (SC; 75 mg or 300 mg) or intravenously (IV; 100 mg or 300 mg) once every 4 weeks for 12 weeks; in Part B, patients received placebo or 300 mg AMG 108 SC, once every 4 weeks for 12 weeks. The clinical effect of AMG 108 was measured in Part B by using the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index pain score. RESULTS: In Part A, 68 patients were randomized, and 64 received investigational product. In Part B, 160 patients were randomized, and 159 received investigational product. AMG 108 was well tolerated. Most adverse events (AEs), infectious AEs, serious AEs and infections, as well as withdrawals from the study due to AEs occurred at similar rates in both active and placebo groups. One death was reported in an 80-year-old patient (Part A, 300 mg IV AMG 108; due to complications of lobar pneumonia). AMG 108 serum concentration-time profiles exhibited nonlinear PK. The AMG 108 group in Part B had statistically insignificant but numerically greater improvement in pain compared with the placebo group, as shown by the WOMAC pain scores (median change, -63.0 versus -37.0, respectively). CONCLUSIONS: The safety profile of AMG 108 SC and IV was comparable with placebo in patients with OA of the knee. Patients who received AMG 108 showed statistically insignificant but numerically greater improvements in pain; however, minimal, if any, clinical benefit was observed. TRIAL REGISTRATION: This study is registered with ClinicalTrials.gov with the identifier NCT00110942.
dc.description.statementofresponsibilityStanley B Cohen, Susanna Proudman, Alan J Kivitz, Francis X Burch, John P Donohue, Deborah Burstein, Yu-Nien Sun, Christopher Banfield, Michael S Vincent, Liyun Ni, and Debra J Zack
dc.identifier.citationArthritis Research & Therapy, 2011; 13(4):R125-1-R125-12
dc.identifier.doi10.1186/ar3430
dc.identifier.issn1478-6354
dc.identifier.issn1478-6362
dc.identifier.orcidProudman, S. [0000-0002-3046-9884]
dc.identifier.urihttp://hdl.handle.net/2440/88984
dc.language.isoen
dc.publisherBioMed Central
dc.rights© 2011 Cohen et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.source.urihttps://doi.org/10.1186/ar3430
dc.subjectHumans
dc.subjectOsteoarthritis, Knee
dc.subjectPain
dc.subjectReceptors, Interleukin-1
dc.subjectAntirheumatic Agents
dc.subjectAntibodies, Monoclonal
dc.subjectInfusions, Intravenous
dc.subjectInjections, Subcutaneous
dc.subjectDouble-Blind Method
dc.subjectDose-Response Relationship, Drug
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.titleA randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_88984.pdf
Size:
427.75 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Medicine publications